Showing results (291-300 of 318) with videos related to
Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinibAlessandro Di Federico, Federica Pecci, Mark Jeng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology CommitteeSylvie Lantuejoul, Ming Sound-Tsao, Wendy A Cooper, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2020
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology CommitteeLynette M Sholl, Fred R Hirsch, David Hwang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.Cancer Cytopathology|May 6, 2017
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimensUmberto Malapelle, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, et al.Cancer Cytopathology|April 26, 2019
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimensPasquale Pisapia, Umberto Malapelle, Gianluca Roma, et al.JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.Pageof 32